Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics
Abstract
Simple Summary Lung neuroendocrine tumors are rare cancers with highly variable biological behavior, ranging from slow-growing tumors to more aggressive forms. Accurate characterization is essential to guide treatment and improve patient outcomes. Conventional radiological imaging, contrast-enhanced CT, remains the cornerstone for anatomical staging, but it provides limited information on tumor biology. Molecular imaging with somatostatin receptor PET/CT and 18F-FDG PET/CT offers complementary insights into receptor expression, metabolic activity, and tumor aggressiveness, supporting prognosis and treatment selection, including eligibility for peptide receptor radionuclide therapy. Emerging quantitative techniques such as radiomics further enhance image analysis by extracting imaging biomarkers associated with tumor heterogeneity and clinical outcomes. This review summarizes current evidence and international recommendations on multimodal imaging in lung NETs, highlighting how the integration of anatomical, molecular, and quantitative imaging may improve disease characterization and support a more personalized, precision medicine approach for patient management.